Inogen Launches Voxi 5: Affordable Stationary Oxygen Concentrator for Home Care

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of Voxi^TM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company’s line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels.

The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy

Developed in collaboration with Yuwell Medical, Voxi 5 presents a viable option for patients seeking reliable stationary oxygen therapy, delivering 1-5 L/min of quiet¹, pure², continuous flow oxygen in a compact³ and efficient design. The device also features caster wheels to allow for worry free movement between rooms in the home, providing enhanced mobility and ease-of-use.

“With Voxi 5, we are fulfilling our mission to make respiratory care more accessible and empowering for patients,” said Kevin Smith, President and Chief Executive Officer. “This launch exemplifies our commitment to innovation, affordability, and enhancing the quality of life for those dependent on oxygen therapy.”

Voxi 5 complements the Inogen At Home® product by offering a value-driven solution for price-sensitive customers or those in need of an additional unit for multi-room use. The Voxi 5 further solidifies Inogen's position as a pioneer in the home oxygen therapy market, offering patients and healthcare providers a reliable and efficient solution for managing chronic respiratory conditions.

Key Features

Quiet Operation: Promoting a peaceful home environment.
Compact Design: Includes lockable casters for ease of movement.
3-Year Sieve Bed Warranty: Providing reliable, long-term performance⁴.
Advanced Filtration: Features an 8-layer internal gas pathway for delivering medical-grade oxygen.

The Voxi 5 is available for purchase through Inogen’s website and authorized partners. For more information, visit Inogen.com/Products.

¹45dBA when measured at 2 m (6.6 ft) from device at 3 L/min and 5 L/min.
²Oxygen Concentration at 1-5 L/min: 87 – 96%.
³Device height of 16.7in.
⁴3-Year Sieve Bed Warranty for a total of 8,000 hours.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

About Yuwell

Since its establishment in 1998, Yuwell has been at the forefront of providing cutting-edge medical device solutions to enhance patient care and improve home healthcare worldwide. Yuwell (002223.SZ) generated over US $1 billion revenue in 2023, and has a broad product portfolio across respiratory treatment, diabetes management, electronic diagnostics products, first aid solutions and rehabilitation, amongst other areas.

With a steadfast commitment to clinical excellence, Yuwell delivers high-quality, medically reliable products that empower healthcare professionals to achieve superior patient outcomes.

With 9 state-of-the-art R&D centers and 7 advanced production facilities, Yuwell's global presence spans over 100 countries and supports more than 300,000 healthcare institutions. Yuwell touches the lives of patients around the globe by bringing professional, user-friendly medical devices into the home.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen’s collaboration with Yuwell; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2024, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

For more information, please visit www.inogen.com.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.